In mid-2024, I covered Novo Nordisk A/S ( NVO ) when its growth path seemed restrained by its capacity to produce enough Wegovy and Ozempic to meet demand, and the Catalent acquisition wouldI have more that 35 years of experience in the investment field having worked as a sell & buy side analyst and portfolio manger for debt and equity funds. I am currently managing a high yield Latam bond fund.My goal, as a Seeking Alpha contributor, is to provide a fundamental view and analysis of companies and funds in a ...